Evidence map›Paper›PMID 42410819›Full record

ArticleMedicine2026

A case report of atypical hemolytic uremic syndrome with a CFH mutation complicated by recurrent posterior reversible encephalopathy syndrome.

Ryotaro Maruyama, Daisuke Takeuchi, Masashi Momose, Tetsuro Amemiya, Ion Terakawa, Kenichi Teshima, Jun Chimura, Kyutaro Noju, Ryu Sugimoto, Kosuke Shiroto and 2 more

Abstract readCase Reports
In one paragraph

Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryotaro MaruyamaDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.ORCID 0009-0006-9325-537
Daisuke TakeuchiDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.
Masashi MomoseDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.
Tetsuro AmemiyaDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.
Ion TerakawaDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.
Kenichi TeshimaDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.
Jun ChimuraDepartment of Emergency and Critical Care Medicine, Aizawa Hospital, Nagano, Japan.
Kyutaro NojuDepartment of Emergency and Critical Care Medicine, Aizawa Hospital, Nagano, Japan.
Ryu SugimotoDepartment of Emergency and Critical Care Medicine, Aizawa Hospital, Nagano, Japan.
Kosuke ShirotoDepartment of Emergency and Critical Care Medicine, Aizawa Hospital, Nagano, Japan.
Kazuki SuganumaDepartment of Emergency and Critical Care Medicine, Aizawa Hospital, Nagano, Japan.
Tomokiyo YamamotoDepartment of General Internal Medicine, Aizawa Hospital, Nagano, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAtypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction, particularly affecting the kidneys and the central nervous system. It is caused by genetic variants or autoantibodies involved in dysregulation of the complement system. Pathogenic variants of the complement factor H (CFH) gene are associated with severe disease and may lead to life-threatening multiorgan failure during the acute phase. We report a case of CFH mutation-positive aHUS complicated by recurrent posterior reversible encephalopathy syndrome (PRES) during the course of treatment. PATIENT CONCERNS: A 32-year-old woman presented with progressive fatigue and acute dyspnea. Laboratory tests revealed hemolytic anemia, thrombocytopenia, and severe acute kidney injury. DIAGNOSES: A peripheral blood smear revealed schistocytes, consistent with TMA. On hospital day 1, she developed generalized tonic-clonic seizures followed by respiratory arrest that required mechanical ventilation. Continuous hemodialysis was initiated for severe renal failure. After the exclusion of thrombotic thrombocytopenic purpura, typical hemolytic uremic syndrome, and secondary causes of TMA, a clinical diagnosis of aHUS was made. Genetic testing later revealed a pathogenic heterozygous CFH variant (c.3572C>T, p.Ser1191Leu), confirming the diagnosis of aHUS.

interventionsAnti-C5 monoclonal antibody (eculizumab) was initiated based on the clinical diagnosis of aHUS. Intensive care management, including mechanical ventilation, renal replacement therapy, plasma exchange, and strict blood pressure control, was also provided. OUTCOMES: During the course of the disease, she developed severe cardiomyopathy and recurrent PRES. Early initiation of complement inhibition combined with intensive care management resulted in complete neurological recovery, and the patient was discharged home without any sequelae. LESSONS: This case highlights that CFH mutation-positive aHUS can be complicated by severe multiorgan dysfunction, including cardiomyopathy and recurrent PRES. Early clinical recognition and prompt initiation of complement inhibition were central to the favorable outcome, while intensive blood pressure control and comprehensive supportive care may have contributed to neurological recovery.

Indexed as

Atypical Hemolytic Uremic SyndromeComplement Factor HPosterior Leukoencephalopathy SyndromeAdultAntibodies, Monoclonal, HumanizedFemaleHumansMutationRecurrenceAntibodies, Monoclonal, HumanizedCFH protein, humanComplement Factor Heculizumabatypical hemolytic uremic syndromecomplement inhibitioncomplement-mediated thrombotic microangiopathyposterior reversible encephalopathy syndrome

Identifiers

PMID42410819
PMCPMC13337012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.